October 30, 2024 07:26 AM EDT
Deals
R&D
Pharma

Bio­gen signs mol­e­c­u­lar glue deal, rais­es year­ly pro­jec­tions

Max Gelman

Senior Editor

Is 2024 the year of mol­e­c­u­lar glues?

Bio­gen on Tues­day be­came the lat­est com­pa­ny to part­ner on the in­creas­ing­ly pop­u­lar sub­ject, team­ing up with pri­vate …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times